CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Expected Return (Loss) on Plan Assets
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Defined Benefit Plan, Expected Return (Loss) on Plan Assets of $8.03 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan
us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2021-12-25 was $2.11M, a 12.31% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2021-09-25 was $1.98M, a 33.48% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2021-06-26 was $1.98M, a 33.50% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for the quarter ending 2021-03-27 was $1.98M, a 33.48% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for fiscal 2025 was $8.03M, a 13.41% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for fiscal 2024 was $7.08M, a 6.34% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for fiscal 2023 was $7.56M, a 3.20% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, expected return (loss) on plan assets for fiscal 2022 was $7.32M, a 9.13% decline from fiscal 2021.
| Period end | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 3 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 6 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 9 month | Defined Benefit Plan, Expected Return (Loss) on Plan Assets 12 month |
|---|---|---|---|---|
| 2025-12-27 | $8.03M 10-K · filed 2026-02-18 | |||
| 2024-12-28 | $7.08M 10-K · filed 2026-02-18 | |||
| 2023-12-30 | $7.56M 10-K · filed 2026-02-18 | |||
| 2022-12-31 | $7.32M 10-K · filed 2025-02-19 | |||
| 2021-12-25 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $4.09M derived: sum of 2 quarters · filed 2024-02-14 | $6.07M derived: sum of 3 quarters · filed 2024-02-14 | $8.06M 10-K · filed 2024-02-14 |
| 2021-09-25 | $1.98M 10-Q · filed 2021-11-03 | $3.97M derived: sum of 2 quarters · filed 2021-11-03 | $5.95M 10-Q · filed 2021-11-03 | $8.35M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | $1.98M 10-Q · filed 2021-08-04 | $3.97M 10-Q · filed 2021-08-04 | $6.37M derived: sum of 3 quarters · filed 2023-02-22 | $9.35M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $1.98M 10-Q · filed 2021-05-04 | $4.39M derived: sum of 2 quarters · filed 2023-02-22 | $7.37M derived: sum of 3 quarters · filed 2023-02-22 | $10.35M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $5.38M derived: sum of 2 quarters · filed 2023-02-22 | $8.37M derived: sum of 3 quarters · filed 2023-02-22 | $11.35M 10-K · filed 2023-02-22 |
| 2020-09-26 | $2.98M 10-Q · filed 2021-11-03 | $5.96M derived: sum of 2 quarters · filed 2021-11-03 | $8.94M 10-Q · filed 2021-11-03 | $12.24M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | $2.98M 10-Q · filed 2021-08-04 | $5.96M 10-Q · filed 2021-08-04 | $9.26M derived: sum of 3 quarters · filed 2022-02-16 | $12.50M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $2.98M 10-Q · filed 2021-05-04 | $6.28M derived: sum of 2 quarters · filed 2022-02-16 | $9.52M derived: sum of 3 quarters · filed 2022-02-16 | $12.75M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $6.54M derived: sum of 2 quarters · filed 2022-02-16 | $9.77M derived: sum of 3 quarters · filed 2022-02-16 | $13.01M 10-K · filed 2022-02-16 |
| 2019-09-28 | $3.24M 10-Q · filed 2020-10-29 | $6.47M derived: sum of 2 quarters · filed 2020-10-29 | $9.71M 10-Q · filed 2020-10-29 | |
| 2019-06-29 | $3.23M 10-Q · filed 2020-08-05 | $6.47M 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | $3.23M 10-Q · filed 2020-05-07 | |||
| 2018-12-29 | $15.52M 10-K · filed 2021-02-17 | |||
| 2017-12-30 | $14.25M 10-K · filed 2020-02-11 | |||
| 2016-12-31 | $14.16M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $16.99M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |